1 |
DLAMINI N, VOERMANS N C, LILLIS S, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis[J]. Neuromuscul Disord, 2013, 23(7): 540-548.
|
2 |
李国刚, 杨林, 朱平. 横纹肌溶解症发病机制研究进展[J]. 中华灾害救援医学, 2019, 7(10): 596-600.
|
|
LI G G, YANG L, ZHU P. Research progress on pathogenesis of rhabdomyolysis[J]. China Disaster Relief Medicine, 2019, 7(10): 596-600.
|
3 |
CHATZIZISIS Y S, MISIRLI G, HATZITOLIOS A I, et al. The syndrome of rhabdomyolysis: complications and treatment[J]. Eur J Intern Med, 2008, 19(8): 568-574.
|
4 |
BÄCKER H C, RICHARDS J T, KIENZLE A, et al. Exertional rhabdomyolysis in athletes: systematic review and current perspectives[J]. Clin J Sport Med, 2023, 33(2): 187-194.
|
5 |
SCALCO R S, SNOECK M, QUINLIVAN R, et al. Exertional rhabdomyolysis: physiological response or manifestation of an underlying myopathy?[J]. BMJ Open Sport Exerc Med, 2016, 2(1): e000151.
|
6 |
CARNEIRO A, VIANA-GOMES D, MACEDO-DA-SILVA J, et al. Risk factors and future directions for preventing and diagnosing exertional rhabdomyolysis[J]. Neuromuscul Disord, 2021, 31(7): 583-595.
|
7 |
VIVANTE A, ITYEL H, PODE-SHAKKED B, et al. Exome sequencing in Jewish and Arab patients with rhabdomyolysis reveals single-gene etiology in 43% of cases[J]. Pediatr Nephrol, 2017, 32(12): 2273-2282.
|
8 |
JUNGBLUTH H, SEWRY C A, MUNTONI F. Core myopathies[J]. Semin Pediatr Neurol, 2011, 18(4): 239-249.
|
9 |
VOERMANS N C, SNOECK M, JUNGBLUTH H. RYR1-related rhabdomyolysis: a common but probably underdiagnosed manifestation of skeletal muscle ryanodine receptor dysfunction[J]. Rev Neurol, 2016, 172(10): 546-558.
|
10 |
CHELU M G, GOONASEKERA S A, DURHAM W J, et al. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse[J]. FASEB J, 2006, 20(2): 329-330.
|
11 |
BOMPAIRE F, ROUX-BUISSON N, MONNIER N, et al. G.P.49 RYR1 mutations in adults with acute rhabdomyolysis episodes[J]. Neuromuscul Disord, 2014, 24(9/10): 809.
|
12 |
GORDON MILLICHAP J. RYR1 mutations, exertional myalgia and rhabdomyolysis[J]. Pediatr Neurol Briefs, 2013, 27(7): 50.
|
13 |
KNUIMAN G J, KÜSTERS B, ESHUIS L, et al. The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutations[J]. J Neurol, 2019, 266(4): 876-887.
|
14 |
KODADEK L, CARMICHAEL II S P, SESHADRI A, et al. Rhabdomyolysis: an American association for the surgery of trauma critical care committee clinical consensus document[J]. Trauma Surg Acute Care Open, 2022, 7(1): e000836.
|
15 |
ESPOSITO P, ESTIENNE L, SERPIERI N, et al. Rhabdomyolysis-associated acute kidney injury[J]. Am J Kidney Dis, 2018, 71(6): A12-A14.
|
16 |
BUTALA B N, KANG A, GURON J, et al. Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual[J]. J Neuromuscul Dis, 2016, 3(1): 115-119.
|
17 |
SCALCO R S, VOERMANS N C, PIERCY R J, et al. Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis[J]. Eur J Neurol, 2016, 23(8): e56-e57.
|
18 |
KUSHNIR A, TODD J J, WITHERSPOON J W, et al. Intracellular calcium leak as a therapeutic target for RYR1-related myopathies[J]. Acta Neuropathol, 2020, 139(6): 1089-1104.
|